US 2026/0297214 A1Published application

Anti-HER2 Antibodies and Immunoconjugates

AssigneeGenentech, Inc.

InventorsXiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski

Life of this patent

Estimating the term…

Abstract

The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.

Claims38

Dependent claims

1-45. (canceled)

A method of treating an individual having a HER2-positive cancer, the method comprising administering to the individual an effective amount of an immunoconjugate, wherein the immunoconjugate comprises a cytotoxic agent and an antibody, and wherein the antibody comprises:

(i)(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
15;
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
16, 20, or 21;
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
17;
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
12;
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
13;
and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
14;
(ii)(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
15;
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
8;
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
22;
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
12;
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
13;
and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
14;
(iii) a light chain variable region comprising the sequence of SEQ ID NO:
10 and a heavy chain variable region comprising the sequence of SEQ ID NO:
11 with one of the following substitutions;
(a) position 53 is serine, position 55 is serine, and position 101 is lysine;
(b) position 53 is methionine and position 55 is serine;
or (c) position 53 is leucine, wherein positions are numbered according to Kabat numbering;
or
(iv) a light chain variable region comprising the sequence of SEQ ID NO:
10 and a heavy chain variable region comprising the sequence of SEQ ID NO:
11, or SEQ ID NO:
11 with one of the following substitutions;
(a) HVR-H2 (SEQ ID NO:
16) is substituted with SEQ ID NO:
8 and HVR-H3 (SEQ ID NO:
17) is substituted with SEQ ID NO:
22;
(b) HVR-H2 (SEQ ID NO:
16) is substituted with SEQ ID NO:
20;
or (c) HVR-H2 (SEQ ID NO:
16) is substituted with SEQ ID NO:
21.

43 more elements

A method of inhibiting proliferation of a HER2-positive cell, the method comprising exposing the cell to an immunoconjugate under conditions permissive for binding of the immunoconjugate to HER2 on the surface of the cell, thereby inhibiting proliferation of the cell, wherein the immunoconjugate comprises a cytotoxic agent and an antibody, and wherein the antibody comprises;

(i)(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
15;
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
16, 20, or 21;
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
17;
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
12;
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
13;
and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
14;
(ii)(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
15;
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
8;
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
22;
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
12;
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
13;
and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
14;
(iii) a light chain variable region comprising the sequence of SEQ ID NO:
10 and a heavy chain variable region comprising the sequence of SEQ ID NO:
11 with one of the following substitutions;
(a) position 53 is serine, position 55 is serine, and position 101 is lysine;
(b) position 53 is methionine and position 55 is serine;
or (c) position 53 is leucine, wherein positions are numbered according to Kabat numbering;
or
(iv) a light chain variable region comprising the sequence of SEQ ID NO:
10 and a heavy chain variable region comprising the sequence of SEQ ID NO:
11, or SEQ ID NO:
11 with one of the following substitutions (a) HVR-H2 (SEQ ID NO:
16) is substituted with SEQ ID NO:
8 and HVR-H3 (SEQ ID NO:
17) is substituted with SEQ ID NO:
22;
(b) HVR-H2 (SEQ ID NO:
16) is substituted with SEQ ID NO:
20;
or (c) HVR-H2 (SEQ ID NO:
16) is substituted with SEQ ID NO:
21.

42 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/366,637Filed 23 Oct 2025
Priority: 12 Sep 2014
Published: 1 Oct 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification28 codes

C07K 16/32
Against material from animals or humans: against translation products of oncogenes
A61K 31/5517
1,4-Benzodiazepines, e.g. diazepam or clozapine: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g.…
A61K 31/675
Phosphorus compounds: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/704
Attached to a carbocyclic compound, e.g. phloridzin: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin,…

Family

Application62/049,594Us provisional application · filed 12 Sep 2014
Application14/851,001Division · filed 11 Sep 2015
Application15/296,454Division · filed 18 Oct 2016
Application16/170,819Division · filed 25 Oct 2018
Application16/721,525Continuation · filed 19 Dec 2019
Application17/720,717Continuation · filed 14 Apr 2022
Application19/366,637Continuation
Application16/721,525Division
US 10,179,820 B2Related patent
US 10,556,966 B2Related patent
US 12,492,263 B2Related patent
US 2016/0096893 A1Published application
US 2017/0174782 A1Published application
US 2019/0177429 A1Published application
US 2020/0255539 A1Published application
US 2023/0041134 A1Published application
US 9,518,118 B2Related patent
US 2026/0297214 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Back to results